# US 2004/0063160 A1 · Assay for directly detecting a biological cell in a body fluid sample

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0063160 A1
- Document ID: US20040063160A1
- Status: Published application
- Kind: A1
- Application number: 10/399,324
- Filed: 2003-08-25
- Published: 2004-04-01
- Earliest claimed: 2000-10-17
- Inventors: Michael Rud Lassen; Morten Breindahl
- Web page: https://patentgrep.com/patent/US20040063160A1

## CPC

- G01N 33/569: for microorganisms, e.g. protozoa, bacteria, viruses
- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to a method for rapid detection of a biological cell and/or a biological particle contained in a fluid sample. The method may be used for rapidly diagnosing a condition in an individual resulting from an infection by a virus, a fungus or a bacteria. The method comprises the further steps of detecting a plurality of infection and/or inflammatory response agents, preferably cytokines, and performing a profile of such agents. The profile is a further indication of the condition being diagnosed. The method for detecting a plurality of infection response agents, preferably cytokines, including the step of performing a profile of such agents, may also be carried out independently of the method for rapidly diagnosing a condition in an individual resulting from an infection by an infectious agent including a virus, fungus and bacteria. In particular the invention relates to a dip stick or like device for rapid detection.

## Claims

### Claim 1

A kit for directly detecting a predetermined biological cell present in a sample in an amount of less than about 2000 per microlitre (10−6 litre), said kit comprising
i) a solid support, and
ii) a plurality of a first targeting species bound to the solid support, said targeting species being capable of directly detecting said predetemined biological cell when it is present in a sample that is brought into contact with the solid support, and
iii) a conjugate comprising a polymeric carrier molecule bound to
iv) at least one first and/or second targeting species capable of directly detecting said predetemined biological cell when it is present in a sample that is brought into contact with the solid support, and
v) at least one labelling species.

### Claim 2 (depends on 1)

Kit according to claim 1, wherein the conjugate comprises
i) a polymeric carrier molecule comprising a plurality of at least one reactive, functional group,
ii) at least one connecting moiety attached to the at least one reactive, functional group,
iii) at least one molecular species selected from the group of molecular species consisting of targeting species and labelling species, wherein each of the molecular species comprises at least one functional group that is reactive with at least one connecting moiety attached to the reagent,
iv) wherein the conjugate comprises at least one molecular species covalently attached thereto via a connecting moiety.

### Claim 3 (depends on 2)

Kit according to claim 2, wherein the polymeric carrier molecule comprises reactive, functional groups in an amount of from about 5 to about 5,000 μmoles per gram of polymeric carrier.

### Claim 4 (depends on 1, 2)

Kit according to any of claims 1 and 2, wherein the biological call capable of being directly detected by a targeting species is a mammalian cell.

### Claim 5 (depends on 1, 2)

Kit according to any of claims 1 and 2, wherein the biological cell capable of being directly detected by a targeting species is a microbial cell.

### Claim 6 (depends on 4, 5)

Kit according to any of claims 4 and 5, wherein the biological cell capable of being directly detected by a targeting species is a virus particle.

### Claim 7 (depends on 6)

Kit according to claim 6, wherein the virus capable of being directly detected by a targeting species belongs to the genus paramyxoviridae.

### Claim 8 (depends on 7)

Kit according to claim 7, wherein the virus is respiratory syncytial virus.

### Claim 9 (depends on 6)

Kit according to claim 6, wherein the virus capable of being directly detected by a targeting species belongs to the family of picorna viruses.

### Claim 10 (depends on 9)

Kit according to claim 9, wherein the picorna virus capable of being directly detected by a targeting species is a foot-and-mouth disease virus.

### Claim 11 (depends on 5)

Kit according to claim 5, wherein the microbial cell is selected from the group consisting of a fungus, a yeast, and a bacterial cell.

### Claim 12 (depends on 1, 2)

Kit according to any of claims 1 and 2, wherein the targeting species is selected from the group of species consisting of antigens; haptens; monoclonal and polyclonal anti-bodies; gene probes; natural and synthetic oligo- and polynucleotides; natural and synthetic mono-, oligo- and polysaccharides; lectins; avidin and streptavidin; biotin; growth factors; hormones; receptor molecules; protein A; and protein G.

### Claim 13 (depends on 1, 2)

Kit according to any of claims 1 and 2, wherein the labelling species is selected from the group of species consisting of proteins; enzymes; toxins; drugs; dyes; fluorescent, luminescent, phosphorescent and other light-emitting substances cells; metal-chelating substances; substances labelled with a radioactive isotope; and substances labelled with a heavy atom.

### Claim 14 (depends on 1, 2)

Kit according to any of claims 1 and 2, wherein the labelling species is selected from the group of species consisting of ferritin, phycoerythrins, phycocyanins, phycobilins, horse-radish peroxidase, alkaline phosphatase, glucose oxidases, galactosidases, ureases, iminodiacetic acid, ethylenediaminetetraacetic acid, diethylenetriaminepentaacetic acid, and desferrioxamine B.

### Claim 15 (depends on 1, 2)

Kit according to any of claims 1 and 2, wherein the first and second targeting species are identical.

### Claim 16 (depends on 1, 2)

Kit according to any of claims 1 and 2, wherein the first and second targeting species are non-identical.

### Claim 17 (depends on 1, 2)

Kit according to any of claims 1 and 2, wherein the polymeric carrier is selected from the group of polymers consisting of natural and synthetic polysaccharides; homopoly amino acids; natural and synthetic polypeptides and proteins; and synthetic polymers having nucleophilic functional groups.

### Claim 18 (depends on 1, 2)

Kit according to any of claims 1 and 2, wherein the polymeric carrier is selected from the group of polymers consisting of polyvinyl alcohols, polyallyl alcohols, polyethylene glycols and substituted polyacrylates.

### Claim 19 (depends on 1, 2)

Kit according to any of claims 1 and 2, wherein the polymeric carrier is selected from the group consisting of dextrans, carboxymethyl-dextrans, starches, hydroxyethyl-starches, hydroxypropyl-starches, glycogen, agarose derivatives, cellulose derivatives and natural gums.

### Claim 20 (depends on 7)

Kit according to claim 7, wherein the polymeric carrier is a dextran.

### Claim 21 (depends on 1, 2)

Kit according to any of claims 1 and 2, wherein the polymeric carrier is selected from the group consisting of hydroxyethyl-celluloses and hydroxypropyl-celluloses.

### Claim 22

Kit according to any of the preceding claims, said kit being in form of a dipstick.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

Kit according to any of the preceding claims 1-22, said kit being adapted for a microsystem.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

Method of detecting a predetermined biological cell present in a sample, said method comprising the steps of
i) contacting the sample with the kit of any of claims 1 to 19, and
ii) detecting a targeting species capable of targeting the predetermined biological cell,
wherein the detection of the targeting species is indicative of the presence of the biological cell in the sample.

### Claim 25 (depends on 24)

Method according to claim 24, wherein the sample is a body fluid sample.

### Claim 26 (depends on 24, 25)

Method according to claim 24 or 25, for further detecting a predetermined inflammatory indicator present in a sample in an amount of less than about 2000 per microlitre (10−6 litre), said method comprising the steps of
i) contacting the sample with a kit comprising
a) a solid support, and
b) a plurality of a first targeting species bound to the solid support, said targeting species being capable of directly detecting said predetermined biological cell when it is present in a sample that is brought into contact with the solid support, and
c) a conjugate comprising a polymeric carrier molecule bound to i) at least one first and/or second targeting species capable of directly detecting said pre-determined biological cell when it is present in a sample that is brought into contact with the solid support, and ii) at least one labelling species, and
ii) detecting a targeting species capable of targeting the predetermined inflammatory indicator,
wherein the detection of the targeting species is indicative of the presence of the predetermined inflammatory indicator in the sample.

### Claim 27 (depends on 24, 25, 26)

Method according to any of claims 24-26, wherein the polymeric carrier molecule comprises i) a plurality of at least one reactive, functional group, ii) at least one connecting moiety attached to the at least one reactive, functional group, and iii) at least one molecular species selected from the group of molecular species consisting of targeting species and labelling species, wherein each of the molecular species comprises at least one functional group that is reactive with at least one connecting moiety attached to the reagent, and wherein the conjugate comprises at least one molecular species covalently attached thereto via a connecting moiety.

### Claim 28 (depends on 24, 25, 26, 27)

Method according to any of claims 24-27, wherein the targeting species is selected from the group of species consisting of antigens; haptens; monoclonal and polyclonal anti-bodies; gene probes; natural and synthetic oligo- and polynucleotides; natural and synthetic mono-, oligo- and polysaccharides; lectins; avidin and streptavidin; biotin; growth factors; hormones; receptor molecules; protein A; and protein G.

### Claim 29 (depends on 24, 25, 26, 27, 28)

Method according to any of claims 24-28, wherein the labelling species is selected from the group of species consisting of proteins; enzymes; toxins; drugs; dyes; fluorescent, luminescent, phosphorescent and other light-emitting substances; metal-chelating substances; substances labelled with a radioactive isotope; and substances labelled with a heavy atom.

### Claim 30 (depends on 24, 25, 26, 27, 28, 29)

Method according to any of claims 24-29, wherein the labelling species is selected from the group of species consisting of ferritin, phycoerythrins, phycocyanins, phycobilins, horseradish peroxidase, alkaline phosphatase, glucose oxidases, galactosidases, ureases, iminodiacetic acid, ethylenediaminetetraacetic acid, diethylenetriaminepentaacetic acid, and desferrioxamine B.

### Claim 31 (depends on 24, 25, 26, 27, 28, 29, 30)

Method according to any of claims 24-30, wherein the polymeric carrier is selected from the group of polymers consisting of natural and synthetic polysaccharides; homopoly amino acids; natural and synthetic polypeptides and proteins; and synthetic polymers having nucleophilic functional groups.

### Claim 32 (depends on 24, 25, 26, 27, 28, 29, 30)

Method according to any of claims 24-30, wherein the polymeric carrier is selected from the group of polymers consisting of polyvinyl alcohols, polyallyl alcohols, polyethylene glycols and substituted polyacrylates.

### Claim 33 (depends on 24, 25, 26, 27, 28, 29, 30)

Method according to any of claims 24-30, wherein the polymeric carrier is selected from the group consisting of dextrans, carboxymethyl-dextrans, starches, hydroxyethyl-starches, hydroxypropyl-starches, glycogen, agarose derivatives, cellulose derivatives and natural gums.

### Claim 34 (depends on 32)

Method according to claim 32, wherein the polymeric carrier is a dextran.

### Claim 35 (depends on 24, 25, 26, 27, 28, 29, 30)

Method according to any of claims 24-30, wherein the polymeric carrier is selected from the group consisting of hydroxyethyl-celluloses and hydroxypropyl-celluloses.

### Claim 36 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

Method according to any of claims 26 to 35, wherein the predetermined inflammatory indicator is selected from the group consisting of agonists from the IL-1 system, preferably IL-1α, IL-1β, IL-1ra, autoantibodies against IL-1α, sIL1-RI and sIL1-RII.

### Claim 37 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

Method according to any of claims 26 to 35, wherein the predetermined inflammatory indicator is selected from the group consisting of agonists from the TNFα system, preferably sTNFR p55 and p75.

### Claim 38 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

Method according to any of claims 26 to 35, wherein the predetermined inflammatory indicator is selected from the group consisting of IL-6 and autoantibodies against IL-6.

### Claim 39 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

Method according to any of claims 26 to 35, wherein the predetermined inflammatory indicator is selected from the group consisting of IL-12, sIL-4R, TNFβ (LT), INFγ, IL4, and IL-10.

### Claim 40 (depends on 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

Method according to any of claims 26 to 35, wherein the predetermined inflammatory indicator is selected from the group consisting of IL-2, RANTES, IL-8, sIL-2R, IL-18, IFNα, and eosinophil cationic protein.

### Claim 41 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

A method for diagnosing an infectious condition in an individual, said method comprising the steps of
v) detecting a predetermined biological cell present in a body fluid sample according to any of claims 24-40, and
vi) diagnosing said infectious condition.

### Claim 42 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

A method for diagnosing an infectious condition in an individual, said method comprising the steps of
iv) detecting a predetermined biological cell present in a body fluid sample according to any of claims 24-40,
v) detecting a predetermined inflammatory indicator present in a body fluid sample according to any of claims 26 to 40, and
vi) diagnosing said infectious condition.

### Claim 43 (depends on 41, 42)

A method for treating an infectious condition in an individual, said method comprising the steps of
iii) performing a diagnosis according to any of the methods of claims 41 and 42, and
iv) treating the infectious condition based on the diagnosis.
